呼吸道合胞病毒疫苗的研究和临床应用

来源 :国外医学(儿科学分册) | 被引量 : 0次 | 上传用户:pgqing
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
简介呼吸道合胞病毒(RSV)的生物学特点和疫苗研究的进展。已经和正在研制的 RSV疫苗包括:(1)福尔马林灭活RSV疫苗;(2)活病毒疫苗,是通过冷传代和温度敏感传代获得的RSV减毒活疫苗,其免疫反应与自然感染相似,感染野生型RSV不加剧病情,能被动获得RSV中和抗体产生保护性免疫反应,是目前正在婴幼儿中试用观察的疫苗;(3)cDNA疫苗,是从RSV cDNA克隆中回收具有感染性重组RSV的活病毒疫苗,在下呼吸道高度减活,可显著提高对野生型-RSV感染的免疫力,安全性好,可构建含有RSV A、B组的 G基因cDNA2价疫苗;(4)载体疫苗,RSV F、G嵌合疫苗由表达含有RSVF和G蛋白的杆状病毒纯化获得;(5)亚单位疫苗,对下呼吸道感染具有保护作用,中和抗体滴度高;(6)合成肽类疫苗等。 Introduction The biological characteristics of respiratory syncytial virus (RSV) and the progress of vaccine research. The RSV vaccines that have been and are being developed include: (1) formalin-inactivated RSV vaccine; (2) live virus vaccine, an attenuated live attenuated RSV vaccine obtained through cold passage and temperature-sensitive passage, whose immune response is associated with natural infection Similarly, infection of wild-type RSV does not exacerbate the disease and can passively obtain a protective immune response against neutralizing antibodies against RSV. Vaccination is currently under trial in infants and young children; (3) cDNA vaccines are recovered from RSV cDNA clones with infectivity Recombinant RSV live virus vaccine, highly deactivated in the lower respiratory tract, can significantly improve the immunity to wild type -RSV infection, safety is good, can construct RSV A, B group G gene cDNA2 price vaccine; (4) vector vaccine , RSV F, G chimeric vaccine purified from baculovirus expressing RSVF and G protein; (5) subunit vaccine, which has protective effect on lower respiratory tract infection and high titer of neutralizing antibody; (6) Vaccines and so on.
其他文献